icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
 
 
 
Long-term Safety and Efficacy of CAB and
RPV as 2-Drug Oral Maintenance Therapy
 
 
  Reported by Jules Levin
CROI 2017 Feb 14-17 Seattle, WA
 
David A Margolis,1Cynthia Brinson,2Graham H Smith,3Joseph J Eron,4Gary J Richmond,5Roger P LeBlanc,6Peter E Williams,7William R Spreen,1Kenneth C Sutton,1Britt S Stancil8 1ViiV Healthcare, Research Triangle Park, NC, USA; 2Central Texas Clinical Research, Austin, TX, USA; 3Maple Leaf Medical Clinic, Toronto, Ontario, Canada; 4University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 5Gary J Richmond MD PA, Ft Lauderdale, FL, USA; 6Clinique OPUS, Montreal, Quebec, Canada; 7Janssen Research and Development, Beerse, Belgium; 8PAREXEL International, Durham, NC, USA
 
CROI/2015: Cabotegravir and Rilpivirine As 2-Drug Oral Maintenance Therapy: LATTE W96 Results....
http://www.natap.org/2015/CROI/croi_77.htm

0217171

0217172

0217173

0217174